CXCL1 and osteosarcoma: To further investigate whether CXCL1-induced VCAM-1 expression and cell migration are CXCR2-dependent mechanisms in osteosarcoma, the antagonist (SB225002), CXCR2 shRNA, and neutralizing antibody of CXCR2 were used for evaluation.